Can prenatal genetic testing tell us if our baby has Wilson disease?

Technically, yes — if both parents’ ATP7B mutations are known, prenatal genetic testing can determine whether a foetus has inherited two faulty copies and therefore has Wilson disease. But knowing that testing is possible is different from knowing whether it is advisable, and this is one of the more complex decisions families with Wilson disease may face.¹

The genetic logic first

Wilson disease is autosomal recessive, meaning a child must inherit a disease-causing ATP7B mutation from both parents to be affected. If only one parent has Wilson disease and the other is confirmed not to be a carrier, the child cannot be affected (though they may be a carrier). If both parents carry mutations — which happens when one parent has Wilson disease and the other happens to be a carrier, or when both parents have the disease — there is a 25% chance with each pregnancy that the child will be affected.²

The first step, before any prenatal testing makes sense, is knowing both parents’ genetic status. This usually means sequencing the ATP7B gene in both parents to identify the specific mutations they carry. If one or both parents have not had formal genetic testing, that is where to start — genetic counseling before or early in pregnancy is the right framework.³

What prenatal tests are available

Two main approaches exist for prenatal genetic diagnosis:

Chorionic villus sampling (CVS): A small sample of placental tissue is taken, typically between 10 and 13 weeks of pregnancy. The foetal cells are then tested for the specific ATP7B mutations identified in the parents. Results are usually available within 1–2 weeks.

Amniocentesis: Foetal cells are collected from amniotic fluid, usually between 15 and 20 weeks. Also tested for parental ATP7B mutations.

Both procedures carry a small procedural risk — typically quoted at around 0.5–1% for pregnancy loss, though estimates vary across studies and institutions. CVS is performed earlier, which matters for decision-making timelines.⁴

A third option, preimplantation genetic testing (PGT), is done before pregnancy: embryos created through IVF are tested for the parental mutations before implantation, so only unaffected (or carrier) embryos are transferred. This avoids the need to make decisions mid-pregnancy but requires IVF.⁵

Why most specialists do not routinely recommend prenatal testing for Wilson disease

This is the important part. Wilson disease is different from many other conditions that are tested prenatally. Here is why the calculation is not straightforward:

Wilson disease is treatable. Unlike conditions where prenatal diagnosis changes the course of pregnancy management (such as chromosomal anomalies affecting viability, or conditions where in-utero intervention is possible), Wilson disease is not manageable before birth. The practical intervention happens after birth — treatment can begin as soon as the diagnosis is confirmed, and when treated, most people with Wilson disease live essentially normal lives.¹

Symptoms are almost never present in infancy. Wilson disease rarely causes any symptoms before 5 years of age. The earliest presentations are typically in mid-to-late childhood or adolescence. This means a newborn who tests positive for Wilson disease has no immediate medical urgency; the condition can be identified and monitored through newborn or childhood screening of family members just as effectively.²

Penetrance is not complete. Not every person who inherits two disease-causing ATP7B mutations will develop clinically significant Wilson disease — recent genomic work has suggested that penetrance may be around 50–70% depending on the variants involved.⁶ This means a prenatal positive result cannot tell you how affected the child will be.

The ethical weight is real. Terminating a pregnancy for a condition that is treatable, that may not cause symptoms for a decade, and that may not fully penetrate raises genuine ethical questions that families and clinicians navigate together. This is not a decision the medical system makes — it is a deeply personal one.

The 2022 AASLD Practice Guidance and the EASL guidelines both acknowledge prenatal testing as technically feasible but stop short of recommending it as a routine intervention, reflecting the general specialist consensus.¹³

Who might have a stronger reason to consider it

This does not mean prenatal testing is never considered. Some situations where a family might have a clearer conversation with a genetics team:

• Both parents have Wilson disease, making a 100% carrier and 25% affected rate a near-certainty
• One parent has Wilson disease with severe neurological manifestations, and the family wants to know in advance in order to plan early monitoring
• The family has strong personal or cultural reasons related to how they want to manage a positive result

In any of these cases, the conversation happens best through a clinical geneticist or genetic counselor who specializes in metabolic or liver disease — someone who can walk through the specific mutations involved, the likely penetrance of those variants, and what the result would actually change in practical terms.

What happens after a positive prenatal test

If prenatal testing does identify a foetus with two pathogenic ATP7B variants, the family and medical team are essentially in the same position as if the diagnosis were made in childhood — except that it is earlier. This allows:

• Preparation: informing the pediatric team who will follow the child
• Early monitoring: baseline copper studies in the newborn period or infancy
• Dietary awareness during childhood (see diet and copper)
• Prompt treatment initiation if symptoms begin to develop

It does not, in current practice, change pregnancy management or delivery planning.

The sibling screening comparison

One important practical point: if you already have a child with Wilson disease, siblings who are already born should be screened for the condition — this is strongly recommended and is standard of care.¹ That kind of testing, done in a child who exists and who can be monitored, is a very different situation from prenatal testing of an embryo or foetus. See family screening for more on how that process works.

Talking this through

If you have Wilson disease and are pregnant or planning pregnancy, this is exactly the kind of question to raise with both your Wilson disease specialist and a clinical geneticist. They can help you understand what your specific mutations mean for penetrance and risk, what the testing options look like in your country or region, and what the results would realistically change.

This is not a decision that has one right answer. It is a personal and medical conversation, and you deserve the time and information to make it thoughtfully.

This article is patient education, not medical advice. Prenatal genetic testing decisions are deeply personal and medically complex. Talk to your specialist team — ideally including a genetic counselor — before deciding whether testing is right for your situation.

References